Tilray’s Aphria RX GmbH Subsidiary Completes First Successful Harvest and Delivery of Medical Cannabis Grown in Germany
Tilray, Inc. (NASDAQ | TSX: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that its wholly-owned subsidiary in Germany, Aphria RX GmbH, has completed the first successful harvest of medical cannabis cultivated in Germany for distribution to German pharmacies. The medical cannabis harvest is the first cultivated under European Good Manufacturing Practices (EU GMP) standard at Tilray’s state-of-the-art 6,000 square meter indoor growing facility in Neumünster, Germany. The subsequent distribution, which was carried out by a distributor on behalf of the German Cannabis Agency and in accordance with all pharmaceutical and narcotic legal requirements, underscores Tilray’s strong foothold and operational excellence within Europe’s key medical cannabis market.
“Our harvest in Germany represents an important milestone in granting access to high-quality and trustworthy medical cannabis to patients and healthcare professionals in Germany,” said Denise Faltischek, Tilray's Head of International and Chief Strategy Officer. “It is a testament to the professionalism and dedication of our team that, despite the challenges of a global pandemic, we remained on track as the first licensed producer to cultivate medical cannabis in Germany. Our achievement would not have been possible without the trust and cooperation of the Federal Institute for Drugs and Medical Devices (BfArM) and the Germany Cannabis Agency, for which we are sincerely grateful.”
Since Germany’s Cannabis as Medicines Act was enacted in March 2017, the country has relied exclusively on imports to meet the growing medical demand currently estimated at well over 100,000 patients. Tilray’s ongoing domestic harvest and production will play an indispensable role in ensuring that patient needs are met with products of the highest quality medical cannabis while at the same time reducing dependence on imported supply.
Irwin D. Simon, Tilray’s Chief Executive Officer, added, “The European Union represents a powerful growth market for us and, among its constituent markets, Germany possesses the greatest potential. We look forward to leveraging our strong medical platform and our multifaceted international operation, which combines in-country cultivation, importation, and large distribution infrastructure, to increase access and availability to high-quality, consistent medical cannabis for all European patients.”
Mr. Simon concluded, “Tilray’s achievement in Germany serves as a strong affirmation that we are competitively differentiated by scale and proven execution skills. As a result, we are poised to transform the industry globally with our highly scalable footprint, portfolio of diverse medical cannabis brands, and compelling products that respond to a wide range of patient and consumer needs. The E.U. is central to our worldwide distribution network, and we look forward to accelerating our progress.”
Tilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from Canada and import medical cannabis products into the E.U. in 2016.
Tilray Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For media inquiries, please contact:
For investor inquiries please contact:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors27.10.2021 18:46:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005677/en/ “We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors. Collaborating with scientific innovators with unique technology platforms and deep domain expertise, such as the GammaDelt
FiRa Consortium Hits Major Milestones in Ultra-Wideband Momentum27.10.2021 18:00:00 CEST | Press release
The FiRa™ Consortium, a catalyst for bringing leading innovators together to drive Ultra-Wideband (UWB) expansion, is today announcing two milestones in the market acceptance of UWB technology. The first is the launch of the initial phase of its certification program aimed at driving interoperability between UWB devices. At the same time, FiRa Consortium is announcing it has now surpassed 100 members, including all of the top handset manufacturers globally, plus market leaders across semiconductors, networking, secure access, and consumer technology. “UWB is fast becoming a pillar of wireless local connectivity technology alongside Wi-Fi and Bluetooth,” said Charlie Zhang, Board Chair of FiRa Consortium. “When combined with the membership momentum we are seeing, our certification program signifies that the market is prepared and ready for broad implementation of UWB across market sectors.” FiRa Consortium’s certification program is the first to provide baseline testing and certificatio
Mitsubishi Corporation Life Sciences to Accelerate Next Wave of Digital Transformation and Business Growth by Switching to Rimini Street Support27.10.2021 18:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Mitsubishi Corporation Life Sciences, a food ingredients manufacturer within Mitsubishi Corporation’s Food Industry Group, has switched to Rimini Street Support for its JD Edwards applications. Switching from the vendor’s support to Rimini Street has enabled the company to dramatically reduce its maintenance costs and free up internal resources for strategic initiatives. By freeing up critical resources – time, money and personnel – Mitsubishi Corporation Life Sciences is able to begin investing in its digital transformation initiatives for the next five to 10 years and establish a foothold for further business expansion, both locally and overseas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005
CURACLE and Théa Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD27.10.2021 17:47:00 CEST | Press release
CURACLE, a Korea-based biopharmaceutical company, today announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation, the sister company of Théa, Europe’s number one independent ophthalmic company with a 150-year history, for the development and commercialization of CURACLE’s CU06-RE, that has the potential to become the first orally administered treatment for diabetic macular edema and wet age-related macular degeneration (wet-AMD). Under the terms of the agreement, CURACLE will receive an upfront payment of $6 million and could receive up to an additional $157.5 million in potential development, regulatory and sales milestones, as well as royalties on sales if CU06-RE is successfully developed, which will entitle CURACLE to receive up to $2 billion in total payments. Théa and CURACLE will closely collaborate on the clinical development of this novel oral drug. CURACLE will be responsible for the Phase I and II clinical studies with TOI
Everbridge Selected to Power the Nationwide Public Alert System for Spain27.10.2021 15:29:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM) and national Public Warning solutions, today announced the selection by Spain to deploy its next-generation population alerting technology to help keep the country’s more than 120 million residents and visitors safe and informed in case of an emergency. Everbridge announced the contract award anonymously in a press release last month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005638/en/ Everbridge Selected to Power the Nationwide Public Alert System for Spain (Graphic: Business Wire) The new country-wide public alert system of Spain will include both Cell Broadcast coverage at the national level, as well as the publication of alerts via the Web and through mobile alerts, powered by Everbridge. The state-of-the-art alert system will reach 99% of the population of Spain, including 47 million residents and nearly 80 million annual v
Earnix Again Recognized Among INSURTECH100’s Most Innovative Global Companies27.10.2021 15:23:00 CEST | Press release
Earnix, a global provider of advanced rating, pricing, and product personalization solutions for insurers and banks, has been again listed in INSURTECH100, recognizing the world’s most innovative InsurTech companies. Each year, a panel of industry experts and analysts led by FinTech Global, a data and research firm, evaluates hundreds of companies in the insurance industry for their business acumen, technological advancements and potential to make a lasting impact on the industry globally. “The insurance industry is going through a transformational period and Earnix is enabling insurers to seize the biggest opportunities and prevail in the face of challenges. With our unparalleled experience, operational efficiency, robust automation, and innovative analytics, we are helping carriers deliver decisions with agility via fully personalized dynamic insurance. We are pleased to be recognized again and will continue to innovate on behalf of insurers and their customers,” said Udi Ziv, CEO at
Airship Names Thomas Butta Chief Strategy and Marketing Officer27.10.2021 15:05:00 CEST | Press release
Airship, the mobile app experience company, today announced Thomas Butta has joined its executive leadership team as Chief Strategy and Marketing Officer, reporting directly to CEO and president Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005300/en/ SaaS branding expert and veteran CMO Thomas Butta joins Airship as Chief Strategy and Marketing Officer (Photo: Business Wire) Butta brings over two decades of marketing leadership and brand positioning expertise, resulting in billions of dollars of enterprise value created through market leadership, strategic acquisitions and record-breaking IPOs. Prior to joining Airship, Butta was CMO at SignalFx, and before that Sprinklr, where he redefined brand value around software observability and customer experience management respectively, resulting in SignalFx’s acquisition by Splunk and Sprinklr’s subsequent public offering under the ticker symbol, CXM (NASDAQ).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom